1-6 of 6
Ellen Napier, NP
Close
Sort by
Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4198.
https://doi.org/10.1182/blood-2018-99-119502
Published: 2018
Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Scott F Huntington, MD MPH, Stephen J. Schuster, MD, Wei He, PhD, Tong Shen, PhD, Heather Walker, MPH, CCRP, Laura Leary, Kylie Boyhen, Jennifer Gill, CRNP, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L. Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, Tanya Latorre, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, RN, Jakub Svoboda, MD, Victoria Addis, MD, Barry Douglas Anderson, MD PhD, Emily Leblond, Yuqin Song, MD PhD, Jun Zhu, MD PhD, Lijuan Deng, MD PhD, Danielle M. Brander, MD, Wei Ding, MD PhD, Allison C. Rosenthal, DO, Han Tun, MD, Anthony R. Mato, MD MSCE
Journal: Blood
Blood (2018) 132 (Supplement 1): 5384.
https://doi.org/10.1182/blood-2018-99-112944
Published: 2018
Journal Articles

Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas

Yuqin Song, MD, Stephen J. Schuster, MD, Wei He, PhD, Jun Zhu, BS, Lijuan Deng, MD, Yingli Sun, MD, Ning Ding, MD, Xiaogan Wang, MD, Jennifer Gill, NP, MSN, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Barry Douglas Anderson, MD PhD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, BCPS, BCOP, Tanya Latorre, BSN, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, Jakub Svoboda, MD, Victoria Addis, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4056.
https://doi.org/10.1182/blood.V130.Suppl_1.4056.4056
Published: 2017
Journal Articles

Long-Term Outcomes of Lenalidomide and Rituximab in Rituximab-Resistant Patients with Indolent B Cell and Mantle Cell Lymphomas

Elise A. Chong, MD, Ellen Napier, NP, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Anthony R. Mato, MD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1492.
https://doi.org/10.1182/blood.V130.Suppl_1.1492.1492
Published: 2017
Journal Articles

Lenalidomide Maintenance after Autologous Stem Cell Transplant in Patients with High-Risk Relapsed/Refractory Lymphomas Is Feasible and Compares Favorably to Historical Controls: Results of a Phase I/II Trial

Jakub Svoboda, MD, Lauren E. Strelec, BA, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Anthony R. Mato, MD, Wei-Ting Hwang, PhD, Sarah Jordan Nagle, MD, Elise A. Chong, MD, Samantha Garrett, Terease S. Waite, MS, RN, JD, MBE, Ellen Napier, NP, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 4639.
https://doi.org/10.1182/blood.V128.22.4639.4639
Published: 2016
Journal Articles

Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma

Jakub Svoboda, MD, Lauren E. Strelec, BA, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Barbara Pro, Stefan Klaus Barta, MDMRCP,MS, Nirav N. Shah, MD, Sarah Jordan Nagle, MD, Elise A. Chong, MD, Ellen Napier, NP, Samantha Garrett, Stephen J. Schuster, MD
Journal: Blood
Blood (2015) 126 (23): 2694.
https://doi.org/10.1182/blood.V126.23.2694.2694
Published: 2015